Article
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Science translational medicine - 30 Mar 2011
Lyubynska Natalya, Gorman Matthew F, Lauchle Jennifer O, Hong Wan Xing, Akutagawa Jon K, Shannon Kevin, Braun Benjamin S
Abstract excerpt
Chronic and juvenile myelomonocytic leukemias (CMML and JMML) are aggressive myeloproliferative neoplasms that are incurable with conventional chemotherapy. Mutations that deregulate Ras signaling play a central pathogenic role in both disorders, and Mx1-Cre, Kras(LSL-G12D) mice that express the Kras oncogene develop a fatal disease that closely mimics these two leukemias in humans. Activated Ras controls...
Topics
- Animals
- Benzamides
- Cell Differentiation
- Diphenylamine
- Extracellular Signal-Regulated MAP Kinases
- GTP-Binding Proteins
- Humans
- MAP Kinase Signaling System
- Mice
- Mice, Inbred C57BL
- Mitogen-Activated Protein Kinase Kinases